Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.

By Jun Guo, L. Si, Y. Kong, K. Flaherty, Xiaowei Xu, Yanyan Zhu, Christopher Corless, Li Li, Haifu Li, X. Sheng and 11 more. Journal of Clinical Oncology, 2011

666 citations recorded by the source corpus.

Subfields: Hematology, Immunology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/64b088ce57849362c9d2e8530514c209f5ea859f